WEBINAR
For the development of a respiratory dry powder formulation, numerous factors need to combine to deliver an effective product. The device, formulation, API, excipients and manufacturing processes all influence the product performance and each need careful consideration during development.

During this webinar, co-hosted by DFE Pharma and Intertek, we review key concepts and techniques in the formulation design and performance testing of these products.

Topics will include the analytical approaches used to characterise these products and the  importance of understanding device performance and resistances. Aerodynamic particle size data interpretation will be discussed and the key factors impacting DPI performance are reviewed. In the second part, it will be shown how lactose particle size impacts the performance of a formulation and how a design space can be identified for lactose particle size.

Supercharge your DPI development, watch our webinar now.


Meet our Experts:

 Mark Parry Pauline Janssen
Mark Parry
Technical Director
Intertek Pharmaceutical Services		Pauline Janssen
Product Application Specialist
DFE Pharma

 

Pauline Janssen is a Product Application Specialist at DFE Pharma. She has been working on application development of excipients based upon fundamental knowledge of excipients and powder physics. She joined DFE Pharma beginning of 2017 and worked as a product developer and application specialist on multiple OSD and DPI projects. Pauline holds a Master’s Degree (cum laude) in Physical Chemistry from the Radboud University in Nijmegen, with an additional specialization in Science, Management and Innovation. Since April 2022, she is also affiliated with the University of Groningen with a PhD student position. Learn more about DFE Pharma | DFE Pharma Privacy Policy

Mark Parry has worked with Intertek Melbourn for 20 years after graduating from Cambridge University and currently works as the Technical Director supporting the wide range of analytical, formulation and product development activities across the company. Mark has worked in a range of pharmaceutical analysis and formulation development areas with a particular focus on inhaled and nasal drug products. Mostly working in the pre-approval stages, Mark’s background includes extensive experience with product and formulation development, as well as method development and validation, stability studies, and pharmaceutical development activities for a wide range of clients across the pharmaceutical industry. Learn more about Intertek's Inhalation Drug Development Expertise

 

 

DISCLAIMER OF ENDORSEMENT. Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favouring by Intertek. The views and opinions of authors expressed herein do not necessarily state or reflect those of Intertek and shall not be used for advertising or product endorsement purposes
DISCLAIMER OF ENDORSEMENT. Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favouring by Intertek. The views and opinions of authors expressed herein do not necessarily state or reflect those of Intertek and shall not be used for advertising or product endorsement purposes